Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own2.90% Shs Outstand53.97M Perf Week-0.50%
Market Cap1.06B Forward P/E- EPS next Y-1.46 Insider Trans-16.90% Shs Float49.38M Perf Month21.85%
Income-71.20M PEG- EPS next Q-0.28 Inst Own95.10% Short Float5.53% Perf Quarter1.57%
Sales6.60M P/S161.12 EPS this Y56.20% Inst Trans23.70% Short Ratio4.94 Perf Half Y-21.50%
Book/sh4.33 P/B4.17 EPS next Y5.20% ROA-47.80% Target Price- Perf Year652.92%
Cash/sh3.94 P/C4.59 EPS next 5Y- ROE-66.70% 52W Range2.25 - 30.38 Perf YTD179.29%
Dividend- P/FCF- EPS past 5Y-0.90% ROI-105.00% 52W High-40.51% Beta0.63
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin25.50% 52W Low703.11% ATR1.01
Employees60 Current Ratio16.20 Sales Q/Q-10.00% Oper. Margin- RSI (14)60.74 Volatility5.33% 6.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.50% Profit Margin- Rel Volume0.84 Prev Close18.01
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume552.48K Price18.07
Recom1.50 SMA206.20% SMA5015.70% SMA200-1.07% Volume463,022 Change0.33%
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Sep-20-21 02:57PM  
08:00AM  
Aug-26-21 04:01PM  
Aug-25-21 06:16AM  
Aug-05-21 10:58AM  
07:00AM  
Jul-30-21 03:00PM  
Jul-08-21 07:00AM  
Jul-06-21 11:49AM  
10:13AM  
Jun-09-21 07:55PM  
11:00AM  
Jun-08-21 04:15PM  
07:46AM  
07:00AM  
May-18-21 01:25AM  
May-17-21 07:00AM  
May-07-21 08:35AM  
07:00AM  
Apr-29-21 05:02PM  
Apr-26-21 01:39AM  
Mar-15-21 07:00AM  
Feb-25-21 07:00AM  
Feb-22-21 07:00AM  
Feb-10-21 07:00AM  
Jan-25-21 02:40PM  
Jan-20-21 01:25PM  
12:13PM  
10:30AM  
08:45AM  
07:32AM  
04:19AM  
Jan-19-21 04:34PM  
04:01PM  
12:10PM  
07:00AM  
Dec-28-20 11:17PM  
Dec-23-20 09:11AM  
Dec-15-20 11:26PM  
07:00AM  
Nov-16-20 04:01PM  
Nov-14-20 07:08AM  
Nov-06-20 12:00PM  
Nov-04-20 08:25AM  
07:00AM  
Oct-29-20 12:35PM  
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
07:00AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gordon David N.Chief Medical OfficerJul 13Sale16.982,63144,675147,447Jul 14 05:32 PM
Ali-Jackson KamilChief Legal OfficerJun 03Sale21.969,492208,421122,196Jun 04 07:52 PM
Monahan JosephChief Scientific OfficerJun 02Sale21.6421,790471,43785,342Jun 02 09:45 PM
Walker NealPresident and CEOJun 02Sale21.6433,260719,7351,232,182Jun 02 09:41 PM
Ali-Jackson KamilChief Legal OfficerJun 02Sale21.6430,119651,664131,688Jun 02 09:47 PM
Gordon David N.Chief Medical OfficerJun 02Sale21.6337,914820,209144,078Jun 02 09:49 PM
Gordon David N.Chief Medical OfficerJun 01Sale23.0114,000322,165181,992Jun 02 09:49 PM
Ali-Jackson KamilChief Legal OfficerJun 01Sale23.0215,000345,299161,807Jun 02 09:47 PM
Ali-Jackson KamilChief Legal OfficerMay 07Option Exercise10.665,41657,735149,034May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 07Sale23.525,416127,392143,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 06Option Exercise10.6615,000159,900158,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 06Sale23.4315,000351,453143,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 05Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 05Sale23.9815,000359,713143,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 04Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 04Sale23.6815,000355,187143,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 03Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 03Sale24.5915,000368,818143,618May 05 08:04 PM
Ruffo FrankChief Financial OfficerApr 26Sale25.8027,339705,228151,720Apr 26 09:45 PM
Ruffo FrankChief Financial OfficerApr 23Sale26.6630,000799,660179,059Apr 26 09:45 PM
Ruffo FrankChief Financial OfficerApr 22Sale26.8430,000805,218209,059Apr 26 09:45 PM
Walker NealPresident and CEOApr 22Sale26.8430,000805,2391,192,427Apr 26 09:43 PM
Mehra AnandDirectorFeb 02Option Exercise18.3414,632268,29830,841Feb 03 05:33 PM